{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:04Z","timestamp":1787003104588,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-024-00744-9","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:05:12Z","timestamp":1722845112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson\u2019s disease pathogenesis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-5716","authenticated-orcid":false,"given":"Konstantin","family":"Senkevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-2258","authenticated-orcid":false,"given":"Lang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea X.","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampton L.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-4325","authenticated-orcid":false,"given":"Mike A.","family":"Nalls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Global Parkinson\u2019s Genetics Program (GP2)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-234X","authenticated-orcid":false,"given":"Ziv","family":"Gan-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.3233\/JPD-223338","volume":"12","author":"S Jewell","year":"2022","unstructured":"Jewell, S., Herath, A. M. & Gordon, R. Inflammasome activation in Parkinson\u2019s disease. J. Parkinsons Dis. 12, S113\u2013s128 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"744_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mds.27874","volume":"35","author":"ME Haque","year":"2020","unstructured":"Haque, M. E. et al. Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov. Disord. 35, 20\u201333 (2020).","journal-title":"Mov. Disord."},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"e55375","DOI":"10.1371\/journal.pone.0055375","volume":"8","author":"G Codolo","year":"2013","unstructured":"Codolo, G. et al. Triggering of inflammasome by aggregated \u03b1-synuclein, an inflammatory response in synucleinopathies. PloS One 8, e55375 (2013).","journal-title":"PloS One"},{"key":"744_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/BJ20150617","volume":"471","author":"A Gustot","year":"2015","unstructured":"Gustot, A. et al. Amyloid fibrils are the molecular trigger of inflammation in Parkinson\u2019s disease. Biochem. J. 471, 323\u2013333 (2015).","journal-title":"Biochem. J."},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.intimp.2017.05.027","volume":"49","author":"QH Shao","year":"2017","unstructured":"Shao, Q. H., Zhang, X. L., Yang, P. F., Yuan, Y. H. & Chen, N. H. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome. Int. Immunopharmacol. 49, 155\u2013160 (2017).","journal-title":"Int. Immunopharmacol."},{"key":"744_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s11064-017-2185-0","volume":"42","author":"Z Mao","year":"2017","unstructured":"Mao, Z. et al. The NLRP3 inflammasome is involved in the pathogenesis of Parkinson\u2019s disease in rats. Neurochem. Res. 42, 1104\u20131115 (2017).","journal-title":"Neurochem. Res."},{"key":"744_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-017-0032-2","volume":"3","author":"S Sarkar","year":"2017","unstructured":"Sarkar, S. et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease. NPJ Parkinsons Dis. 3, 30 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"744_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41531-018-0061-5","volume":"4","author":"KM von Herrmann","year":"2018","unstructured":"von Herrmann, K. M. et al. NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 24 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"744_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1670-6","volume":"17","author":"Z Fan","year":"2020","unstructured":"Fan, Z. et al. Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease. J. Neuroinflamm. 17, 11 (2020).","journal-title":"J. Neuroinflamm."},{"key":"744_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41531-020-00147-6","volume":"7","author":"FL Anderson","year":"2021","unstructured":"Anderson, F. L. et al. Plasma-borne indicators of inflammasome activity in Parkinson\u2019s disease patients. NPJ Parkinsons Dis. 7, 2 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3233\/JPD-223290","volume":"12","author":"LTN Nguyen","year":"2022","unstructured":"Nguyen, L. T. N. et al. Role of NLRP3 inflammasome in Parkinson\u2019s disease and therapeutic considerations. J. Parkinsons Dis. 12, 2117\u20132133 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","volume":"629","author":"EV Minikel","year":"2024","unstructured":"Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic evidence on clinical success. Nature 629, 624\u2013629 (2024).","journal-title":"Nature"},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"744_CR14","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9, eaag1166 (2017).","journal-title":"Sci. Transl. Med."},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"G Consortium","year":"2020","unstructured":"Consortium, G. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318\u20131330 (2020).","journal-title":"Science"},{"key":"744_CR16","doi-asserted-by":"publisher","first-page":"eaat8464","DOI":"10.1126\/science.aat8464","volume":"362","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human brain. Science 362, eaat8464 (2018).","journal-title":"Science"},{"key":"744_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04558-1","volume":"9","author":"T Qi","year":"2018","unstructured":"Qi, T. et al. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat. Commun. 9, 2282 (2018).","journal-title":"Nat. Commun."},{"key":"744_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mds.27659","volume":"34","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat, C. et al. Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and \u03b1-synuclein mechanisms. Mov. Disord. 34, 866\u2013875 (2019).","journal-title":"Mov. Disord."},{"key":"744_CR19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","volume":"34","author":"H Iwaki","year":"2019","unstructured":"Iwaki, H. et al. Genomewide association study of Parkinson\u2019s disease clinical biomarkers in 12 longitudinal patients\u2019 cohorts. Mov. Disord. 34, 1839\u20131850 (2019).","journal-title":"Mov. Disord."},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/mds.28342","volume":"36","author":"MMX Tan","year":"2021","unstructured":"Tan, M. M. X. et al. Genome-wide association studies of cognitive and motor progression in Parkinson\u2019s disease. Mov. Disord. 36, 424\u2013433 (2021).","journal-title":"Mov. Disord."},{"key":"744_CR21","doi-asserted-by":"publisher","first-page":"e1672","DOI":"10.1212\/WNL.0000000000011630","volume":"96","author":"X Kang","year":"2021","unstructured":"Kang, X. et al. Tumor necrosis factor inhibition and parkinson disease: a mendelian randomization study. Neurology 96, e1672\u2013e1679 (2021).","journal-title":"Neurology"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JPD-239901","volume":"13","author":"K McFarthing","year":"2023","unstructured":"McFarthing, K. et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update. J. Parkinsons Dis. 13, 427\u2013439 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"744_CR23","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336\u20132337 (2010).","journal-title":"Bioinformatics"},{"key":"744_CR24","doi-asserted-by":"publisher","first-page":"e1010624","DOI":"10.1371\/journal.pgen.1010624","volume":"19","author":"SW Choi","year":"2023","unstructured":"Choi, S. W. et al. PRSet: pathway-based polygenic risk score analyses and software. PLoS Genet. 19, e1010624 (2023).","journal-title":"PLoS Genet."},{"key":"744_CR25","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.28549","volume":"36","author":"H Iwaki","year":"2021","unstructured":"Iwaki, H. et al. Accelerating medicines partnership: Parkinson\u2019s disease. genetic resource. Mov. Disord. 36, 1795\u20131804 (2021).","journal-title":"Mov. Disord."},{"key":"744_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-125","volume":"15","author":"AR Carson","year":"2014","unstructured":"Carson, A. R. et al. Effective filtering strategies to improve data quality from population-based whole exome sequencing studies. BMC Bioinformatics 15, 125 (2014).","journal-title":"BMC Bioinformatics"},{"key":"744_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ajhg.2012.06.007","volume":"91","author":"S Lee","year":"2012","unstructured":"Lee, S. et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am. J. Hum. Genet. 91, 224\u2013237 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"744_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajhg.2013.05.010","volume":"93","author":"S Lee","year":"2013","unstructured":"Lee, S., Teslovich, T. M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare variants in sequencing association studies. Am. J. Hum. Genet. 93, 42\u201353 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"744_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481\u2013487 (2016).","journal-title":"Nat. Genet."},{"key":"744_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03371-0","volume":"9","author":"Y Wu","year":"2018","unstructured":"Wu, Y. et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat. Commun. 9, 918 (2018).","journal-title":"Nat. Commun."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00744-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:14:10Z","timestamp":1722845650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-024-00744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1038\/s41531-024-00744-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"3 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.G.O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanquabio Guidepoint, Lighthouse and Deerfield. C.X.A., M.A.N., and H.L.L.\u2019s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc. and as an advisor to Neuron23 Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}